The estimated Net Worth of Peter Devlin is at least $10.2 Million dollars as of 27 November 2018. Peter Devlin owns over 18,000 units of Insulet stock worth over $9,792,390 and over the last 15 years Peter sold PODD stock worth over $456,849.
Peter has made over 10 trades of the Insulet stock since 2011, according to the Form 4 filled with the SEC. Most recently Peter bought 18,000 units of PODD stock worth $6,480 on 27 November 2018.
The largest trade Peter's ever made was exercising 30,000 units of Insulet stock on 8 April 2014 worth over $249,000. On average, Peter trades about 10,605 units every 126 days since 2009. As of 27 November 2018 Peter still owns at least 43,000 units of Insulet stock.
You can see the complete history of Peter Devlin stock trades at the bottom of the page.
Peter's mailing address filed with the SEC is C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD, MA, 01730.
Over the last 18 years, insiders at Insulet have traded over $64,849,299 worth of Insulet stock and bought 175,262 units worth $7,280,516 . The most active insiders traders include Jonathan Silverstein, Elizabeth H Weatherman und Samuel D Colella. On average, Insulet executives and independent directors trade stock every 19 days with the average trade being worth of $2,473,148. The most recent stock trade was executed by Timothy J Scannell on 10 September 2024, trading 5,000 units of PODD stock currently worth $1,129,200.
insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down
Insulet executives and other stock owners filed with the SEC include: